• DWITYA ELVIRA Department of Internal Medicine, Allergic and Clinical Immunology Division, Dr. M. Djamil General Hospital/Medical Faculty, Andalas University, Padang-Indonesia.


Objective: The aim of this study is to prove that there are Forkhead Box P3 (FOXP3) T-regulator promoter polymorphisms in Graves’ disease and to analyze the association between FOXP3 T-regulator promoter polymorphisms with transforming growth factor (TGF)-β levels.

Methods: This study was an observational study with cross-sectional comparative study design. Consecutive sampling was conducted in patients with Graves’ disease who came to the outpatient clinic and treated in Dr. M. Djamil Hospital, Padang. Blood sampling was performed on 30 Graves’ subjects and 30 control subjects based on inclusion and exclusion criteria. DNA isolation, primary construction, and polymorphism identification by polymerase chain reaction method and blood sample examination by enzyme-linked immunosorbent assay techniques method for TGF-β examination were performed in this study.

Results: The results of this study obtained the most age of patients with Graves’ disease is 30–40 years with the female gender. Graves’ patient group was found to have 86.7% of single nucleotide polymorphisms (SNP) rs3761548 polymorphism, and 61.3% had SNP rs2232365 polymorphism followed by 26.7% polymorphism of SNP rs3761547 and rs3761549, and no SNP rs2232364 polymorphism was found. In Graves’ group, the mean value of TGF-β was 1030.01±277.64 ng/ml, significantly higher than the control group. Statistical analysis showed a significant relationship between polymorphism of the FOXP3 promoter gene and TGF-β level with p<0.05.

Conclusion: This study proves that there are polymorphisms of the FOXP3 promoter gene in Graves’ patients, especially SNP rs3761548 and rs2232365. The polymorphism of the FOXP3 promoter gene has a significant association with TGF-β levels.

Keywords: Forkhead box P3 promoter gene polymorphism, Graves’ disease, Interleukin-10, Transforming growth factor-β, T-regulator


1. Idrose AM. Acute and emergency care for thyrotoxicosis and thyroid storm. Acute Med Surg 2015;2:147-57.
2. Brent GA. Graves’ disease. N Engl J Med 2008;358:2594-605.
3. Girgis C, Champion B, Wall J. Current concepts in graves’ disease. Ther Adv Endocrinol Metab 2011;2:135-44.
4. Decroli E, Elvira D, Aprilia A. The effect of thionamide to TRH, TSH, IL-4, T-reg, and anti-TPO in graves’ disease. Indones J Pharm 2019;30:122-7.
5. Decroli E, Manaf A, Syahbuddin S. Immunologic and hormonal effects of propylthiouracil treatment using maintenance dose in graves’ disease. Acta Med Indones 2014;46:314-9.
6. Davies TF. Infection and autoimmune thyroid disease. J Clin Endocrinol Metab 2008;93:674-6.
7. Lombardi A, Menconi F, Greenberg D, Concepcion E, Leo M, Rocchi R, et al. Dissecting the genetic susceptibility to graves’ disease in a cohort of patients of Italian origin. Front Endocrinol 2016;7:1-7.
8. Ban Y, Tozaki T, Tobe T, Ban Y, Jacobson E, Concepcion E, et al. The regulatory T cell gene FOXP3 and genetic susceptibility to thyroid autoimmunity: An association analysis in caucasian and Japanese cohorts. J Autoimmun 2007;28:201-7.
9. Ngalamika O, Zhang Y, Yin H, Zhao M, Gershwin M, Lu Q. Epigenetics, autoimmunity and hematologic malignancies: A comprehensive review. J Autoimmun 2012;39:451-65.
10. Li H, Chen Q. Genetic susceptibility to graves’ disease. Front Biosci 2013;18:1080-7.
11. Bossowski A, Borysewicz-Sanczyk H, Wawrusiewicz-Kurylonek N, Zasim A, Szalecki M, Wikiera B, et al. Analysis of chosen polymorphisms in FoxP3 gene in children and adolescents with autoimmune thyroid diseases. Autoimmunity 2014;47:395-400.
12. Lei ZW, Yang ZL. Association between FOXP3, FOXE1 gene polymorphisms and risk of differentiated thyroid cancer in Chinese Han population. Mol Biol 2015;4:1-5.
13. Wang YM, Ghali J, Zhang GY, Hu M, Wang Y, Sawyer A. Development and function of FOXP3 (+) regulatory T cells. Nephrology 2016;21:81-5.
14. Peterson R. Regulatory T-cells: Diverse phenotypes integral to immune homeostasis and suppression. Toxicol Pathol 2012;40:186-204.
15. Oda J, Hirata B, Guembarovski R, Watanabe M. Genetic polymorphism in FOXP3 gene: Imbalance in regulatory T-cell role and development of human diseases. J Genet 2013;92:163-71.
16. Chen W, Konkel JE. TGF-beta and “adaptive” Foxp3(+) regulatory T cells. J Mol Cell Biol 2010;2:30-6.
17. Chen X, Oppenheim JJ. Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity. FEBS Lett 2011;585:3611-8.
18. Tran D. TGF-beta: The sword, the wand, and the shield of FOXP3(+) regulatory T cells. J Mol Cell Biol 2012;4:29-37.
19. Kristensen B, Hegedus L, Lundy S, Brimnes M, Smith T, Nielsen C. Characterization of regulatory B cells in graves’ disease and hashimoto’s thyroiditis. PLoS One 2015;10:e0127949.
20. Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol 2008;173:600-10.
21. Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. Front Neuroendocrinol 2014;35:347-69.
22. Khan D, Ahmed SA. The immune system is natural target for estrogen action: Opposing effects of estrogen in two prototypical autoimmune diseases. Front Immunol 2016;6:1-8.
23. Owen CJ, Eden JA, Jennings CE, Wilson V, Cheetham TD, Pearce S. Genetic association studies of the FOXP3 gene in graves’ disease and autoimmune addison’s disease in the United Kingdom population. J Mol Endocrinol 2006;37:97-104.
24. Wang B, Shao X, Song R, Xu D, Zhang J. The emerging role of epigenetics in autoimmune thyroid diseases. Front Immunol 2017;8:1-13.
25. Yan N, Zhou JZ, Zhang JA, Cai T, Wang Y, et al. Histone pre-acetylation and increased histone deacetylases in peripheral blood mononuclear cells from patients with graves’ disease. Mol Cell Endocrinol 2015;414:143-7.
26. Hassannia H, Abediankenari S, Ghaffari J. FOXP3 and TGF-? gene polymorphisms in allergic rhinitis. Iran J Immunol 2011;8:218-25.
27. Elvira D, Darwin E. Role of pro-inflammatory and regulatory cytokines in pathogenesis of graves’ disease in association with autoantibody thyroid and regulatory FoxP3 T-cells. Int J Med Health Sci 2017;11:69-72.
28. Elvira D. The role of T-regulatory expression in autoimmune thyroid disease and its association with thyroid antibody. J Autoimmun Disord 2016;2:19.
29. Sarkar D, Chakraborty A, Bhattacharya C, Singh LH, Chandra AK. Exploration of goitrogenic/antithyroidal potentiality of bamboo-shoots in relation to thiourea. Int J Pharm Pharm Sci 2017;9:7-12.
30. Saptarini NM, Wibowo MS, Gusnidar T. Correlation study of age, disease duration, and erythrocyte sedimentation rate among the Indonesian rheumatoid arthritis patients. Int J Pharm Pharm Sci 2015;7:274-7.
31. Decroli E, Manaf A, Syahbuddin S, Waspadji S, Dillasamola D. The role of survivin and raf-1 kinase against enhancement of pancreatic beta-cell apoptosis in patients with Type 2 diabetes mellitus. Asian J Pharm Clin Res 2018;11:344-7.
32. Santoso DI, Yunita S, Paramita N, Andraini T, Kartinah NT, Bayani GF, et al. Effect of Hibiscus sabdariffa Linn on IL-6 and TNF-? levels in overtrained rat heart. Int J App Pharm 2019;11:42-5.
31 Views | 36 Downloads
How to Cite
ELVIRA, D. “CORRELATION BETWEEN POLYMORPHISMS OF FOXP3 T-REGULATORY PROMOTOR GENE WITH TGF-β IN PATIENTS WITH GRAVES’ DISEASE”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 13, no. 7, May 2020, pp. 133-5, doi:10.22159/ajpcr.2020.v13i7.37717.
Original Article(s)